1. Lower profit margin has deflated Biosensors’ net profit by 80 percent. 2. Operations environment to remain tough for BIG as they shift management. 3. Biosensor in hopes to get pass the wind with new product, BioFreedom, which was granted permission for a US-based clinical trial by the FDA Biosensors International Group (BIG) announced its 4Q14 [...]
Created by Collin Seow | Jul 28, 2014